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Sleeping sickness is a neglected tropical disease affecting rural communities in sub-Saharan
Africa. The reduction in the number of reported cases in recent years indicates that disease
transmission is under control. However, many aspects of patient management still need to
be  improved. Undiagnosed patients or inappropriate treatment due to an incorrect determi-





for  new diagnostic and staging tools to keep the disease under control and to improve the
clinical care of patients. This review describes the most promising biomarkers proposed so
far  for the diagnosis and stage determination of patients suffering from sleeping sickness,
with a particular emphasis on their translation into diagnostic tools for ﬁeld applications.
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.  Introduction
uman African trypanosomiasis (HAT), also known as sleep-
ng sickness, is a neglected tropical disease endemic in
ub-Saharan Africa, mainly affecting rural communities [1].
t is a focal disease caused by an extracellular protozoa
elonging to the Trypanosoma genus. After infection, parasites
roliferate in blood and lymph, giving rise to the ﬁrst stage (S1)
f the disease. In the absence of treatment, it evolves into the
econd stage (S2) due to parasite invasion of the central ner-
ous system (CNS). Even though the number of newly reported
ases of HAT in 2009 was approximately 10,000, the real num-
er is estimated to be three times higher [2]. In most cases,
leeping sickness is fatal if untreated. Transmission of the dis-
ase is currently considered to be under control and it may
ven be heading towards eradication [3], however, due to the
ack of vaccines and prophylaxis, great efforts will be needed
o maintain the status quo or even improve the current situa-
ion. Patient management is still not considered optimal, with
umerous cases missed at diagnosis or not correctly staged
nd treated. This review aims to summarize the most interest-
ng ﬁndings in terms of novel biomarkers and tools proposed
o far to improve the management of patients affected by
uman African trypanosomiasis.
.  Human  African  trypanosomiasis  (HAT):
pidemiological  and  clinical  aspects
leeping sickness is endemic in 200 known foci in 36 countries
n sub-Saharan Africa [4] and the associated disease burden
as estimated at 1,609,041 DALYs lost in 2004 [5,6]. Two sub-
pecies of Trypanosoma brucei parasites are responsible for the
isease: T. b. gambiense and T. b. rhodesiense. These forms are
esistant to the trypanosome lytic factor present in human
lood, whereas other species such as T. b. brucei, T. vivax and
. congolense,  are sensitive to it [7,8]. The Serum Resistance
ssociated (SRA) gene, coding for the SRA protein, has been
dentiﬁed as the resistance factor in T. b. rhodesiense [9,10],
hile T. b. gambiense’s resistance mechanism is still unknown.
oth parasites are transmitted to humans by tsetse ﬂies of the
lossina genus, and undergo a cyclic transmission between the
ector and the human host [1,2]. Importantly, the geographical
istribution of the tsetse ﬂy in sub-Saharan Africa determines
than 90% of all reported HAT cases. T. b. rhodesiense causes
acute infection in eastern Africa and is responsible for less
than 10% of reported cases [3,11]. The two forms of parasite
are geographically separated by a line across Uganda [12].
Historically, disease prevalence followed in waves  of epi-
demics mainly linked to the socio-political instability of the
affected countries. The resolutions adopted by the WHO
and NGOs during the 1990s led to a consistent reduction
in the number of reported cases, quantiﬁed by decreases
of 69% for the gambiense form and 21% for the rhodesiense
form, during the period 1997–2006 [3]. Currently, disease
transmission is considered to be under control, with 19 of
the 36 endemic countries registering no new cases in 2009
[11].
Sleeping sickness progresses through two stages. The ﬁrst
stage (stage 1, S1), or haemolymphatic stage, occurs after an
incubation period that can vary from 1 to 3 weeks after the bite
of the tsetse ﬂy. This stage is characterized by the proliferation
of parasites in the bloodstream and the lymphatic system. If S1
patients are not properly treated, the disease progresses to the
second stage (stage 2, S2) or meningo-encephalitic stage, when
parasites invade the CNS [13]. The disease is considered to be
fatal if untreated [14]. The speed of progression from S1 to S2
varies according to the infecting parasite: for T. b. gambiense,  S1
can last for months or years before evolving into S2, while the
evolution of T. b. rhodesiense HAT from S1 to S2 occurs within
a few weeks of infection [14].
In both forms of HAT, early stage patients present unspe-
ciﬁc clinical symptoms and signs [15]. Stage 1 disease can often
mimic  other illnesses endemic in the same regions, such as
malaria and HIV, which can even coexist in patients affected
by sleeping sickness [16].
As the disease evolves into S2, the clinical symptoms and
signs become more  speciﬁc, with the appearance of neu-
rological disorders of different types as a consequence of
meningo-encephalitis, including impaired motor functions,
tremors, psychiatric changes and coma [14]. The clinical man-
ifestations of the two forms of HAT are different and, generally,
T. b. gambiense patients present more  evident neurological
disorders [15]. A characteristic neurological complication of
sleeping sickness, which gives the disease its name, is a dys-
function of the sleep-wake cycle, with daytime sleepiness and
alterations of the normal sleep patterns with the appearance
of sleep onset REM periods (SOREMPs) [17].
The diagnostic workﬂow for HAT patients consists of three
he location of the disease within the so-called tsetse belt
2].
T. b. gambiense is responsible for chronic infection in 24
ountries in western and central Africa, accounting for morephases. The ﬁrst phase, the serological screening, consists
in mass population examination using the Card Agglutina-
tion Test for Trypanosomiasis (CATT) to identify patients
potentially affected by T. b. gambiense.  In all positive patients,
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diagnosis of the disease must be conﬁrmed through detection
of the parasites in any body ﬂuid, using different parasito-
logical techniques (see Section 4). Patients with a positive
parasitological diagnosis of sleeping sickness are then sub-
jected to a lumbar puncture for cerebrospinal ﬂuid (CSF)
examination and stage determination (see Section 5). Finally,
patients are treated and followed for 2 years to conﬁrm cure
(Fig. 1).
The choice of drug to treat HAT patients strictly depends
on the form of the infecting parasite and on the stage of the
disease. This aspect underlines the importance of a correct
stratiﬁcation. Stage 2 patients need to be treated with drugs
able to cross the blood–brain barrier (BBB) and to diffuse into
the central nervous system (CNS), but as these drugs can be
highly toxic, the exposure of S1 patients to them should be
limited. Stage 1 patients can be relatively safely treated with
pentamidine (T. b. gambiense)  or with suramin (T. b. rhode-
siense) [18]. Interestingly, low levels of pentamidine have been
detected in patients’ CSF. Consequently, this drug has been
proposed for the treatment of patients having a white blood
cell (WBC) count between 5 and 20 L−1 and absence of para-
sites in the CSF (intermediate patients) [19]. However this is
not recommended as a routine clinical practice.
Fig. 1 – Example of a classical diagnostic workﬂow for T. b.
gambiense sleeping sickness. The diagnostic workﬂow for T.
b. rhodesiense HAT does not comprise serological screening
through the CATT. CATT: Card Agglutination Test for
Trypanosomiasis; mHCT: microhaematocrit centrifugation;
mAECT: mini-anion exchange centrifugation; T−: absence
of parasites in CSF; T+: presence of parasites in CSF.
Adapted from [2]. i c s 1 ( 2 0 1 3 ) 12–24
Until recently, the treatment of late stage patients was
based on melarsoprol, an organo-arsenic compound effective
in treating both gambiense and rhodesiense diseases. How-
ever, this drug is associated with severe side effects and
causes a post-treatment reactive encephalopathy (PTRE) in
4.7% of gambiense patients and 8% of rhodesiense patients; it
is fatal for 44% and 57% of them, respectively [18]. Nowa-
days, S2 T. b. gambiense patients can be treated with either
eﬂornithine or nufurtimox–eﬂornithine combination therapy
(NECT) [11,20]. These drugs are safer than melarsoprol, but
they are characterized by complicated administration, high
cost, logistic constraints and a number of non-negligible side
effects [18,21,22].
After treatment, patients cannot be considered immedi-
ately cured as relapses can occur, especially for late stage cases
[23]. Most HAT relapses are the result of a decreased efﬁcacy
of melarsoprol in some foci [18,24], probably due to the devel-
opment of resistant parasite strains [25]. To detect treatment
failures early or to conﬁrm cure, HAT patients need to be fol-
lowed for 2 years after treatment. Follow-up visits consist of
blood tests and CSF examinations for the presence of para-
sites, and of CSF WBC  counts, performed at the end of the
treatment and repeated every 6 months for 2 years [26].
According to the WHO,  relapse is diagnosed following the
detection of trypanosomes in any body ﬂuid at any follow-up
time. Patients without detected parasites, but having a WBC
count 20 L−1 in CSF at any follow-up time, are classiﬁed as
probable relapse. Both relapses and probable relapses are con-
sidered as treatment failures and should be re-treated [26].
Despite WHO  recommendations, globally accepted guidelines
are still missing and different diagnostic criteria are applied
in the ﬁeld [26,27].
3.  Why  do  we  need  HAT  biomarkers?
A peculiar characteristic of trypanosome is its mechanism of
antigenic variation. In hosts’ body ﬂuids, the surface of the
parasite is covered with variant surface glycoproteins (VSGs)
and 10% of the parasite genome encodes for different VSGs
[28]. One VSG type is expressed at a time, and the trypanosome
switches to a different one as soon as the host immune
response becomes effective. This mechanism has two main
consequences: the development of waves  of parasitemia in
patients’ blood and the inefﬁciency of the host’s immune
response in achieving a complete clearance of the parasite
[29]. Moreover, this process of antigenic variation has so far
hampered the development of anti-HAT vaccines [30]. Con-
sequently, prompt case detection, diagnosis and treatment of
patients according to the stage of the disease is essential to
keep the disease under control.
According to a deﬁnition given in 2001 by a working group
of the U.S. National Institutes of Health (NIH), a biomarker
– or biological marker – is a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention [31]. Many examples of clini-
cally useful biomarkers can be found in the literature [32–34].
The development of new disease biomarkers for clinical use
has been recently described as a 5-step process consisting of:
t r a n s l a t i o n a l p r o t e o m i c s 1 ( 2 0 1 3 ) 12–24 15
Fig. 2 – Summary of the most promising tools proposed to improve the diagnosis of sleeping sickness and stage
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i) discovery and veriﬁcation of potential candidates; (ii) vali-
ation through the development of pre-clinical assays; (iii)
esting of biomarkers’ utility in prospective longitudinal stud-
es; (iv) prospective screening; and (v) determination of the
mpact of the biomarker on disease control and management
35]. Although proposed for cancer biomarkers, this workﬂow
an be applied to other pathologies.
A number of putative molecular markers for different
pplications on HAT have been proposed since the 1970s. In
articular, due to the limitations of current methods, most of
he studies aimed to ﬁnd new targets to improve diagnosis and
tage determination of the disease. However, one important
spect when considering biomarkers for HAT is their trans-
ation into diagnostic tools to be applied in the ﬁeld. To be
linically useful, a HAT biomarker should be translated into
 rapid, easy to use, highly stable and cheap test that can
e applied in the ﬁeld. In the following paragraphs, we will
escribe the current clinical practice for diagnosis and stage
etermination of HAT, paying particular attention to the pit-
alls and challenges raised by the proposed biomarkers and
ools (Fig. 2).
.  HAT  diagnosis  and  diagnostic  markers
.1.  Current  diagnostic  practice
he introduction of the CATT for serological mass popula-
ion screening in 1978 [36], considerably increased the rate
f detected cases by active case ﬁnding. This has had impor-
ant consequences on disease control [37]. This test is based
n the detection of antibodies to T. b. gambiense parasite in
atients’ blood. Despite its utility and its high speciﬁcity and
ensitivity (95% and 87–98%, respectively), it is not consid-
red a diagnostic gold standard [16]. Decreased accuracy of
he CATT has been reported in some foci where particular
trains of trypanosomes are present, as well as false posi-
ive results due to cross-reactions with antibodies to other
arasites [38,39]. Serological screening is followed by para-
itological examination of body ﬂuids for the detection of
rypanosomes. The different methods of parasite detection
n blood, such as microhaematocrit centrifugation (mHCT)
r mini-anion exchange centrifugation (mAECT), have beeniagnostics (FIND, www.ﬁnddiagnostics.org).
reviewed elsewhere [16]. However, parasitological tools are
often not sensitive enough to detect parasites which may be
present in patients’ body ﬂuids in low numbers [28,29]. Fur-
thermore, the lower parasitemia typical of T. b. gambiense,
compared to T. b. rhodesiense, might be responsible for the
missed diagnosis of 20–30% of T. b. gambiense cases [40]. These
limitations highlight the need for new tools to improve the
screening and diagnosis of sleeping sickness.
4.2.  Alternative  diagnostic  biomarkers  and  tools
4.2.1.  Antibody-based  diagnostic  tools
In order to improve efﬁcacy in detecting HAT seroposi-
tive cases, alternatives to the CATT have been proposed.
The test that has shown the highest potential as a new
mass population-screening tool is the Latex/T. b. gambi-
ense (Latex/T.b.g.). Like the CATT, this test detects antibodies
against the parasite in patients’ blood through an aggluti-
nation reaction. The main advantage of Latex/T.b.g. is the
detection of three different variant antigen types: LiTat 1.3, 1.5
and 1.6 [41], while the CATT detects only LiTat 1.3. As a conse-
quence, Latex/T.b.g. produces fewer false negative results, but
a decreased sensitivity has been reported in some foci char-
acterized by a high expression of LiTat 1.3 [42]. However, the
increased number of antigen targets did not solve the problem
of false positives due to cross-reactions with other parasites.
Contradictory results have been reported by different studies
comparing Latex/T.b.g. and the CATT, or the standard CATT
with improved versions of the same test (i.e. micro-CATT,
CATT-EDTA) [43] [42,44,45].
Recently, new antibody-based rapid assays, not requir-
ing a cold chain, have been developed for the serological
diagnosis of T. b. gambiense HAT: HAT SERO K-SeT, HAT Sero-
Strip [121] and SD BIOLINE HAT (http://www.ﬁnddiagnostics.
org/media/press/121206.html). Two of these promising tools –
HAT SERO K-SeT and SD BIOLINE HAT, both developed as lat-
eral ﬂow assays – are currently under ﬁeld evaluation in the
Democratic Republic of the Congo.4.2.2.  Parasite  antigen  detection
A diagnostic test based on the detection of parasite anti-
gens, rather than antibodies developed by the host against the
invading pathogens, would represent an efﬁcient alternative
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and a substantial gain in terms of speciﬁcity. One limitation
of antibody-based diagnostic tools is their lack of utility dur-
ing the follow-up. Neither CATT nor Latex/T.b.g. can, in fact,
be used for the evaluation of outcomes after treatment, since
the detected antibodies persist in the host after the clearance
of parasites [46].
An approach widely used to identify new potential targets
for the development of antigen-based diagnostic tools is the
investigation of the parasite proteome and sub-proteomes.
It has been suggested that the interaction between host
and pathogens plays a central role in the onset of the dis-
ease as well as for the severity of the clinical presentation
[47].
During the last few years, pathogeno-proteomics has been
regarded as a very promising approach for the identiﬁcation of
new diagnostic and prognostic markers, or for the identiﬁca-
tion of new therapeutic targets [48,49]. Pathogeno-proteomics
is based on the analysis of the cross-talk between the parasite,
the host and the vector, with the aim of characterizing the cru-
cial mechanisms which lead to the disease [48], The proteome
and sub-proteomes of trypanosomes, at different stages of
development in both human hosts and vectors, have been
extensively studied using this approach. A number of differ-
entially expressed trypanosome proteins have been identiﬁed
as typical of the parasite’s different life stages [50]. However,
most of the published studies focused on the characterization
of Trypanosoma brucei brucei parasite. Further investigations
translating these ﬁndings to the two subspecies infectious to
humans are strongly needed, since this type of approach could
highlight new targets for the development of new tools and
drugs.
4.2.3.  Trypanosome  DNA  ampliﬁcation
The ampliﬁcation of speciﬁc trypanosome DNA sequences by
polymerase chain reaction (PCR) for the diagnosis of HAT was
ﬁrst proposed during the 1990s [38]. Different assays have been
developed based on the ampliﬁcation of TBR 1–2 sequences
[51,52], minicircles of the kienetoplast DNA (kDNA) [53] and
ribosomal RNA genes [54], which are shared by the different
Trypanozoon subgenus. Alternatively, the ampliﬁcation of T. b.
gambiense speciﬁc glycoprotein (TgsGP) [55], or of sequences of
the gene encoding for the SRA protein speciﬁc for T. b. rhode-
siense [56] have also been evaluated.
Beside the high speciﬁcity of PCR for the diagnosis of HAT,
most of the published studies were limited by the investigation
of a relatively small number of patients; by the lack of compar-
ison to the diagnostic utility of other tests (such as the CATT);
or by the lack of the determination of the diagnostic accuracy
on suspected cases rather than only on parasitologically con-
ﬁrmed cases. This latter aspect is particularly important for
assays based on the use of primers able to detect the forms of
parasite non-infectious to humans in addition to T. b. gambi-
ense and T. b. rhodesiense.
The value of PCR as a diagnostic tool was recently evaluated
in a retrospective study conducted in the Democratic Republic
of the Congo (D.R.C.); it was reported to be 99% speciﬁc and
88% sensitive [57]. However, the same authors showed that
the accuracy of this approach can rapidly vary according to a
number of conditions, including retreatment cases, for which
a very low sensitivity was reported [57]. i c s 1 ( 2 0 1 3 ) 12–24
The interesting diagnostic potential of PCR is also weak-
ened by its low applicability as a ﬁeld test, since it requires
high-tech instruments and trained personnel. The most
promising alternative ampliﬁcation method, with huge poten-
tial for ﬁeld application, is the loop-mediated isothermal
ampliﬁcation of DNA (LAMP) [58]. This technique, originally
developed for the detection of a variety of pathogens [58,59],
was recently adapted for the diagnosis of sleeping sickness
[60]. LAMP relies on the isothermal ampliﬁcation of multi-
ple speciﬁc DNA regions in the parasites, followed by the
visualization of the results through the development of a ﬂu-
orescence signal or turbidity [61].
Mugasa et al. systematically analyzed the most accurate
studies focusing on the evaluation of the diagnostic accuracy
of the different molecular diagnostic methods for HAT. They
reported 98.7% SE and 99.8% SP in case-control studies, and
98.6% SE and 94.5% SP in non case-control studies [62]. Due
to the novelty of the LAMP as a new diagnostic tool for HAT,
few studies are available in the literature and a meta-analysis
evaluation of the overall accuracy of this approach cannot be
done yet.
4.2.4.  Host  proteomics
Despite the huge efforts made to identify new tools to accu-
rately diagnose HAT, few of them focused on the systematic
evaluation of the effects induced by the presence of parasites
in the host. A widely used approach to discover diagnostic
biomarkers is the application of different omics approaches
to investigate human body ﬂuids in healthy and pathologi-
cal conditions: these include proteomics, transcriptomics and
metabolomics [63–65]. These approaches, whether considered
individually or together, have shown themselves to be use-
ful for a number of different applications, however only a few
studies have been published on sleeping sickness.
The most important proteomics study for HAT diagnostic
application is probably the work of Papadopoulos and col-
leagues [66]. By using SELDI-TOF MS, they aimed to identify
new serum biomarkers for the diagnosis of HAT through the
detection of speciﬁc HAT serum proteomics signatures [66].
The authors identiﬁed some protein signatures that were
able to signiﬁcantly discriminate between parasitologically
conﬁrmed HAT patients and control patients suffering from
other illnesses. However, none of their protein signatures was
accurate enough and only combinations obtained using dif-
ferent data mining algorithms could improve the diagnostic
accuracy of the putative marker signatures. As stated by the
same authors, this type of approach cannot be applied in the
ﬁeld and the results obtained should be expanded through
the identiﬁcation of the proteins corresponding to the differ-
ent signatures for further evaluation. Despite this interesting
approach, investigating human body ﬂuids for protein signa-
tures still remains a discovery approach. The results proposed,
in fact, were not compared to current diagnostic tools, such as
the CATT, and protein identiﬁcation remains a crucial step for
further investigation and improvement of our understanding
of the pathophysiology of this disease.In a more  recent study, Manful and colleagues applied
a different proteomics approach to identify diagnostics try-
panosome antigens in human body ﬂuids [67]. They assessed
the ability of antibodies present in serum samples, obtained






















































st r a n s l a t i o n a l p r o t 
rom infected and non-infected subjects, to recognize proteins
rom procyclic and bloodstream forms of T. b. brucei parasites.
hey proposed tbHSP70 as an interesting candidate for the
evelopment of a multiplexed diagnostic tool. However, this
pproach was limited by the use of T. b. brucei parasites instead
f the human infecting forms, gambiense and rhodesiense, and
he obtained results were not investigated further.
.  HAT  stage  determination  and  staging
arkers
.1.  Current  staging  practice
he determination of the stage of sleeping sickness is essen-
ial for the correct treatment of patients. The progression of
he disease from the ﬁrst to the second stage is characterized
y parasite penetration into the CNS and the development of
 meningo-encephalitis [14]. The detection of trypanosomes
n CSF by microscopy alone has limited sensitivity, even after
oncentration by centrifugation [68,69]. The number of para-
ites circulating in CSF can be very low, generating false
egative results. To try to increase sensitivity, the detection
f parasites has been complemented by the counting of WBC
n CSF. Consequently the WHO  recommends that all patients
howing evidence of trypanosomes in their CSF and/or a num-
er of CSF white blood cells >5 L−1, should be diagnosed and
reated as S2 [70]. WBC  counting is, however, not speciﬁc to
leeping sickness, has poor reproducibility, and the cut-off
t 5 cells/L is controversial [3,71,72]. A number of countries
pply a staging cut-off at 10 or 20 WBC/L  [71], following the
bservation that some patients – with WBC/L  between 5 and
0 and no parasites in CSF – could be effectively treated with
tage 1 drugs. Based on these observations, the possibility of
ntroducing a third stage, called the “intermediate” or “early-
ate” stage, has been proposed [19,73].
.2.  Alternative  staging  biomarkers  and  tools
ue to the importance of an accurate stage determination of
AT for the correct management of patients [74], many  stud-
es have focused on the search for alternative methods, to
vercome the limitations of existing ones. Only a few exam-
les in the literature focus on HAT plasma markers. The most
nteresting published results mainly concern the observation
f decreased levels of molecules such as NO, IFN- [75] or
L-10 [76] in post-treatment plasma. Others compare plasma
arkers in HAT patients and control subjects [77], rather than
ooking at the comparison of pre-treatment plasma mark-
rs between stages. The majority of staging studies focused
n CSF the body ﬂuid that best reﬂects the physiological or
athological state of the central nervous system due to its
roximity to CNS structures [78,79]. CSF is mainly produced at
he choroid plexus, where it is separated by blood circulation
hrough the blood–CSF barrier. It is produced at a ﬂow-rate of
pproximately 500 mL/24 h [80] and its composition is strictly
egulated by the selectivity of the BBB [79]. The CSF proteome
s for its most part (80%) composed of proteins derived from
lood and, as in plasma, albumin and immunoglobulins repre-
ent approximately 70% of the total amount of CSF protein [81]. c s 1 ( 2 0 1 3 ) 12–24 17
The remaining 20% of CSF proteins are produced in the brain,
although they are rarely considered brain speciﬁc [80,82]. Since
late stage HAT is characterized by a meningo-encephalitis
[14,83] and that CSF examination is part of the current diag-
nostic workﬂow, the reasoning for looking for novel disease
progression markers in this body ﬂuid seems pertinent.
5.2.1.  CSF  antibodies
Alterations in the protein content of CSF are of particular
clinical utility for many  neurological disorders. An increased
protein concentration can be indicative of either a BBB dys-
function or an increased intrathecal synthesis of proteins. The
quotients of albumin (QAlb) and immunoglobulin (QIg) are used
to evaluate and quantify this dysfunction [79,80,82], and the
latter can be particularly helpful to indicate an inﬂammatory
process occurring in the brain [82,84].
The increased concentration of immunoglobulins in the
CSF of late stage HAT patients, with IgM being the pre-
dominant class, has been known since the 1980s [85]. This
observation agrees with the absence of the switch between
IgM and IgG, and the low decay of CSF antibodies characteris-
tic of the humoral immune response in the brain [82]. More
recently, it has been demonstrated that an increased frac-
tion of IgM of intrathecal origin in S2 HAT patients [73,86] is
indicative of the presence of a brain inﬂammatory process not
associated to damage of the BBB. IgM, and in particular those
of intrathecal origin, are currently considered as the best alter-
native to a WBC  count for staging T. b. gambiense HAT. A rapid
agglutination test for the evaluation of IgM concentration in
CSF has been developed (Latex/IgM) and a high correlation
between the ﬁnal Latex/IgM titer and intrathecal IgM produc-
tion has been shown [87,88]. Despite this method has high
accuracy for stage determination [88], strong enough evidence
to support its introduction into clinical practice is still missing.
Moreover, Latex/IgM exhibited limited utility for the evalua-
tion of outcomes after treatment. Indeed, Latex/IgM combined
with a WBC  count accurately detected relapses at 18 months
after treatment, but IgM normalized very slowly over time in
cured patients [89,90].
IgM – both total and intrathecal fractions – has not been the
only type of antibody investigated for the staging of HAT. Other
antibody-based approaches have been proposed, although
their results were less successful. A couple of studies high-
lighted an increased concentration in late stage patients’ CSF
of auto-antibodies directed to neuroﬁlament and galactocere-
broside proteins, expressed in neurons and oligodendrocytes,
respectively [91,92]. It has been proposed that the production
of these auto-antibodies might be associated with cerebral
damage in S2 patients. However, the staging utility of these
molecules was not investigated further.
5.2.2.  Cytokines  and  chemokines
Hosts react to the presence of the invading parasites not only
with the production of antibodies and auto-antibodies, but
also by modulating a number of immune-effectors. Studies
in experimental models (mainly mouse, rat and primate), or
in human post-mortem samples, have in fact indicated that
the host immune response plays a central role in HAT patho-
genesis [13,93]. However, many  aspects of the mechanisms
elicited by the parasite in the host, as well as the temporal
18  t r a n s l a t i o n a l p r o t e o m i c s 1 ( 2 0 1 3 ) 12–24
Fig. 3 – Principal mechanisms involved in the neuro-inﬂammation of HAT. The sequence of events leading to the invasion
of the CNS and the development of a neuro-inﬂammatory response has been derived from studies in animal models and
human samples. M: macrophage.
Figure adapted from [14,83].
relation between parasite penetration into the CNS, the
development of neuro-inﬂammation and the onset of clinical
manifestations of late stage HAT still need to be understood.
The neuro-inﬂammation typical of late stage HAT presents
some peculiar characteristics, including the early activation
of macrophages and astrocytes, the presence of perivascular
inﬁltrates of inﬂammatory cells (perivascular cufﬁng) and of
Mott cells (plasma cells containing IgM), and the up-regulation
of inﬂammatory cytokines [83,94–96] (Fig. 3). It is not sur-
prising, therefore, that a number of studies have focused on
the evaluation of immune mediators as indicators of HAT
CNS involvement. Activated astrocytes and macrophages are
two important sources of cytokines and chemokines in the
brain. It has been proposed that the balance between pro-
and anti-inﬂammatory cytokines can determine the outcome
and clinical manifestations of the disease [13]. The levels of
pro- and anti-inﬂammatory cytokines and chemokines have
been measured for the investigation of their staging potential
in a number of studies on T. b. gambiense or T. b. rhodesiense
patient cohorts. The most interesting results in terms of
staging potential have been obtained with IL-10 [76], IL-6,
IL-8 [97], CCL-2, CCL-3, CXCL8, IL-1 [77], lipocalin 2 and SLPI
[98]. Cytokines and chemokines also play a central role in the
process of leukocyte recruitment to the site of inﬂammation
and transmigration across the BBB [99,100]. Thus, they areassociated with the increased number of WBC  observed in CSF
in late stage HAT, which represents the basis of current stage
determination. These mechanisms of leukocyte recruitment
require a chemotactic gradient and a number of interactions
between the surface molecules of leukocytes and endothelial
cells (integrins and adhesion molecules), which mediate
the passage of leukocytes through the basement membrane
[83,100]. Leukocytes are then sequestrated in the perivascular
space, and matrix metalloproteinases are needed for the fur-
ther passage through the basement membrane and the glial
limitans to reach the brain parenchyma [101,102]. The poten-
tial involvement in these mechanisms has been evaluated for
a number of molecules – including ICAM-1, VCAM-1, MMP-9,
MMP-2, e-selectin, CXCL10 and CXCL13 – in both animal
models and human samples. Some of these putative markers
showed good ability in stratifying patients [98,103–106].
We recently evaluated the levels of the most promising
staging markers proposed so far (CXCL10, CXCL13, ICAM-1,
VCAM-1, MMP-9, IgM, neopterin and B2MG), on a multicen-
tre cohort comprising 512 T. b. gambiense patients enrolled
in Chad, D.R.C. and Angola [107]. Using a ﬁrst screening, we
conﬁrmed the high staging power of all the molecules (AUC
>90%) and neopterin was validated as a new alternative to
WBC  counting for the stage determination of HAT. The value
of this metabolite – a known indicator of the activation of





















































pt r a n s l a t i o n a l p r o t 
he cellular immune response [108] – as HAT marker was fur-
her supported by its very accurate evaluation of outcomes
fter treatment. It was able to shorten the follow-up for cured
atients as soon as 6 months after treatment, with 87% SP and
2% SE [90]. Another important aspect supporting the poten-
ial for neopterin, as both a point-of-care test and test-of-cure
or sleeping sickness, is the possibility of developing a rapid
ateral ﬂow assay for ﬁeld applications [109].
The same selection of markers was also assessed on a
mall population of T. b. rhodesiense patients. Different staging
bilities were observed for the two forms of disease [110], sug-
esting that the neuropathogenesis of the two diseases may
e different, as already proposed [111].
The majority of the studies proposing new staging markers
howed high correlation between the levels of these molecules
nd the severity of the signs of neurological damage, a condi-
ion indicative of an advanced stage of disease [14]. Even so, a
ecent work on T. b. rhodesiense reported that even if the levels
f some cytokines (IL-6, IL-10 and TNF-) were elevated in the
SF of S2 patients, there was no correlation between the lev-
ls of the molecules, the disease progression and the extent
f the neurological effects [112].
This observation may also underline the lack of speciﬁcity
f these immunological markers. In some of the published
tudies, a useful approach has been found in the combination
f multiple markers into panels to increase staging accuracy
104,105,112]. Further investigations in longitudinal prospec-
ive studies are needed to evaluate the markers proposed so
ar, in terms of beneﬁts for patients and for clinical practice.
.2.3.  Trypanosome  DNA  ampliﬁcation
he ampliﬁcation of speciﬁc parasite DNA sequences by PCR,
lready proposed for the diagnosis of sleeping sickness, has
lso been evaluated for the determination of the stage of the
isease. A study assessing CSF PCR for stage determination
nd treatment outcome evaluation was recently published.
his reported the good staging accuracy of PCR (i.e. SE and SP
bove 80%), but limited utility during post-therapeutic follow-
p (speciﬁcity and sensitivity varied between 50% and 80%)
57].
These results conﬁrmed previously published data on the
trong potential of PCR compared to other approaches for
tage determination, including LATEX/IgM and WBC  count, if
he presence of parasites in CSF was considered as the only
old standard [113]. However, it is well known that the detec-
ion of parasites in CSF is not sensitive enough to be used as a
nique staging method. Further studies are needed to evalu-
te the real added value of PCR compared to the standard stage
etermination tools. Another aspect that should be taken into
ccount is the low utility of PCR during the post-therapeutic
ollow-up, since positive results are obtained from patients
onsidered cured [57].
As already highlighted for diagnosis, the application of
tandard PCR methods in the ﬁeld is not practicable. The
etection of parasites through ampliﬁcation of speciﬁc DNA
equences in CSF using the LAMP approach is a promising
lternative for ﬁeld application and interesting preliminary
esults have been reported [114].
An alternative method for easier WBC  counts has also been
roposed. Based on the observation of the presence of a high c s 1 ( 2 0 1 3 ) 12–24 19
number of B-cells expressing CD19 in the CSF of S2 patients,
the proposed method consisted in counting this B-cell pop-
ulation through the formation of rosettes that can be easily
visualized and counted by microscopy [115,116].
5.2.4.  Host  proteomics
All the biomarkers and tools for the stage determination of
HAT described in the previous paragraphs derived from cur-
rent knowledge of the mechanisms and manifestations of
the disease’s progression. However, one of the most com-
mon  approaches for the discovery of disease biomarkers is
the systematic evaluation of the changes in protein expression
between healthy and pathological conditions. As already high-
lighted, the application of proteomics on sleeping sickness at
the host level is an unexplored ﬁeld. Only one study has been
published so far comparing the CSF proteome of S1 and S2
HAT patients [117]. By applying complementary proteomics
discovery approaches, it has been shown that a number of
host proteins were over-expressed in the CSF of S2 patients.
Not surprisingly the 2-DE proteome maps of S2 patients
showed a huge increase in the amount of immunoglobu-
lins, in accord with previous knowledge of an elevation of
immunoglobulins in CSF with disease progression [85]. Two of
the 73 differentially expressed proteins, beta-2-microglobulin
and osteopontin, were further conﬁrmed to be accurate dis-
criminators of S1 and S2 patients (AUC% = 91.5 and 84.8,
respectively) [117], however after veriﬁcation other proteins
on the list may be found to be more  useful.
5.2.5.  Polysomnography
One of the typical clinical manifestations of late stage HAT
is the alteration of the normal sleep-wake cycle; this is man-
ifested by daytime somnolence, night wakefulness, and the
appearance of SOREMPs [17]. These alterations of sleep pat-
terns have been studied for a long time and in recent years the
potential value of these manifestations as staging biomark-
ers has been highlighted [118]. Sleep patterns can in fact
be monitored non-invasively using polysomnography. This
consists of recording of an electroencephalogram (EEG), an
electro-oculogram (EOG) and an electromyogram (EMG) fol-
lowed by an analysis of the recorded data [17]. In particular,
it has been shown that late stage patients have a high num-
ber of SOREMPs during their sleep, which are not restricted
to night time, but occur in the day time too. These distur-
bances tend to disappear after melarsoprol treatment [17].
Despite the interesting data from polysomnography, its stag-
ing ability has only been investigated on a small number of
patients or in one-case studies, thus a complete evaluation of
the approach has not been possible yet [17,119,120]. Although
it requires bulky, high-tech material, long periods of exami-
nation (24–48 h) and trained personnel, its major advantage is
that it is non-invasive.
6.  Translation  of  HAT  biomarkers  into  ﬁeld
practice:  successes  and  pitfallsIn this review we have described the most interesting
biomarkers proposed so far for the diagnosis and the staging
of HAT, with particular emphasis on their translation into ﬁeld
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practice (Fig. 2). The nature of sleeping sickness – a neglected
tropical disease – implies that for novel biomarkers to be
useful, they should also have the potential to be translated
into a cheap (i.e. <$1), easy to use and rapid (i.e. less than
15 min) ﬁeld test. This step towards a realistic ﬁeld test
represents the bottleneck for the utility of new biomarkers.
Furthermore, the ability to use the same biomarker (and thus
the same test) for multiple clinical applications to do with
HAT (e.g. staging and follow-up) would mean signiﬁcant cost
savings in terms of production and personnel training.
The introduction of the CATT for mass population
screening probably represents the greatest success in the bat-
tle against sleeping sickness of the last 30 years, together with
the introduction of eﬂornithine and NECT for the treatment of
late stage patients. The use of the CATT and the application of
a policy of proactive diagnostic testing, has contributed sub-
stantially to the reduction in the number of new cases and
transmission of the disease. Due to its well-described limi-
tations, the most important being the impossibility of using
it for the serological screening of T. b. rhodesiense, a number
of alternatives to the CATT have been proposed. However,
very promising tests such as the Latex/T.b.g. did not show
a real gain in terms of accuracy or applicability in the ﬁeld
compared to the CATT. Currently, the most promising alter-
native tools are represented by the rapid, new serological
diagnostic tests, SD BIOLINE HAT (http://www.ﬁnddiagnostics.
org/media/press/121206.html) and HAT Sero K-SeT [121]. The
forthcoming evaluation of these tests in the ﬁeld is keenly
awaited, since their introduction into clinical practice would
represent an important improvement.
The molecular diagnosis of HAT, which has the great advan-
tage of being highly speciﬁc, has evident constrains for ﬁeld
application. Only recently, with the development of the LAMP
approach, has the translation of DNA ampliﬁcation into a ﬁeld
test become feasible.
One of the most fascinating staging approaches is
polysomnography, probably due to its non invasiveness. It is
unlikely that this method will become applicable for large-
scale stage determination in rural areas, but as suggested by
the same authors, it may ﬁnd a niche application in paedi-
atric cases, for which it would be preferable to avoid a lumbar
puncture [119].
Great hopes currently rest on the immune-based detection
of biomarkers, such as neopterin. Despite their lack of speci-
ﬁcity, these may prove to be very useful to replace WBC  counts
for the determination of stage, in combination with the detec-
tion of parasites in CSF. Furthermore, they could possibly be
used as test-of-cure markers during post-therapeutic follow-
up, thus extending their ﬁeld of application. The translation of
this type of molecule into immune-based lateral ﬂow assays is
underway, for the rapid determination of disease stage and/or
the evaluation of post-treatment outcomes. For some of them,
this has already been done for other applications [109].
7.  Concluding  remarks  and  future
perspectives
Thanks to the disease control programmes and resolutions
adopted over the last few years, HAT is currently considered i c s 1 ( 2 0 1 3 ) 12–24
under control and complete elimination of the disease is no
longer seen as a utopia [3]. However, to reach this goal and to
not underestimate the disease, as has already happened in the
past [37], patient management needs to be improved, above all
in terms of diagnosis and treatment. Effective case detection
and therapeutic intervention is essential to reduce disease
transmission by decreasing the number of reservoirs. Huge
efforts have been made over the last 30 years to improve clini-
cal practice with speciﬁc regard to HAT patients by identifying
biomarkers and developing new diagnostic tools. However,
some widely used approaches for biomarker discovery in
malignant conditions, including proteomics, have not been
able to ﬁnd clear application in sleeping sickness.
A few published studies [66,67,117] showed interesting
results highlighting the potential utility of proteomics. It and
other omics disciplines, by giving a global overview of the
transcriptomic, proteomic and/or metabolic state of the sam-
ples analyzed, could help to achieve a better understanding of
the mechanisms leading to the onset and the progression of
sleeping sickness. Additionally, proteomics may also be useful
in highlighting differences between the two forms of infecting
parasites – T. b. gambiense and T. b. rhodesiense – at both host
and parasite levels.
Another ﬁeld that should probably be better explored is the
identiﬁcation of plasma markers for both stage determination
and the evaluation of treatment outcomes. Plasma markers
would have the great advantages of reducing the number of
lumbar punctures currently necessary, making sample col-
lection easier and less invasive, and increasing attendance at
follow-up visits.
In conclusion, great efforts have been made by the WHO,
NGOs and research institutions over the last few decades to
actively regulate the transmission of sleeping sickness and
to reduce the number of cases. Alternative diagnostic tools
to improve patient management have been proposed and
some of them have shown very promising results, but further
studies are needed to introduce these new tools into clinical
practice.
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